Press Releases
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
-
Mar 3, 2025
Acquisition to expand Interventional Cardiology Therapies offerings with ultrasound-based renal denervation therapy for treatment of hypertension MARLBOROUGH, Mass., March 3, 2025 /PRNewswire/ --...
-
Feb 17, 2025Il catetere di ablazione FARAWAVE™ NAV e il modulo FARAVIEW™, combinati con il sistema di mappatura di Boston Scientific, consentono una cartografia durante l'ablazione per elettroporazione.
MILANO, Italia, 17 febbraio 2025 – Boston Scientific Corporation (NYSE: BSX) ha annunciato oggi di aver ottenuto il marchio CE per il catetere di ablazione FARAWAVE™ NAV, una tecnologia di...
-
Feb 17, 2025El catéter de ablación FARAWAVE™ NAV y el software FARAVIEW™, combinados con el sistema de mapeo de Boston Scientific, permiten una cartografía durante la ablación por electroporación.
MADRID, España 17 de febrero de 2025 – Boston Scientific Corporation (NYSE: BSX) anunció hoy que ha obtenido el marcado CE para el catéter de ablación FARAWAVE™ NAV, una tecnología de...
-
Feb 17, 2025FARAWAVE™ NAV Ablationskatheter und FARAVIEW™ Software in Kombination mit dem Boston Scientific Mapping-System ermöglichen Mapping für die Pulsed Field Ablation
DÜSSELDORF, Deutschland - 17. Februar 2025 – Die Boston Scientific Corporation (NYSE: BSX) hat die CE-Kennzeichnung für den navigationsfähigen FARAWAVE™ NAV-Ablationskatheter zur Behandlung...
-
Feb 17, 2025FARAWAVE™ NAV Ablation Catheter and FARAVIEW™ Software combine with Boston Scientific mapping system to provide mapping during pulsed field ablation
LONDON, United Kingdom, 17 February, 2025 – Boston Scientific Corporation (NYSE: BSX) today announced it has received CE mark for the navigation-enabled FARAWAVE™ NAV Ablation Catheter for the...
-
Jan 16, 2025
First phase of ADVANTAGE AF clinical trial achieves safety and effectiveness endpoints for treatment of drug-resistant, symptomatic, persistent atrial fibrillation with the FARAPULSE™ Pulsed...
Nov 16, 2024Data also demonstrates that the stroke risk reduction device is as effective as oral anticoagulants for patients with atrial fibrillation following a cardiac ablation MARLBOROUGH, Mass. and...
-
Nov 15, 2024
Boston Scientific Corporation (NYSE: BSX) today announced the close of its acquisition of Axonics, Inc. (Nasdaq: AXNX), a medical technology company focused on the development and...
-
Oct 24, 2024Diagnostic algorithm shown to detect early signs of worsening heart failure and reduce hospitalisations for patients with cardiac implantable electronic devices
HEMEL HEMPSTEAD, United Kingdom, 24 October, 2024 – Boston Scientific (NYSE: BSX) announced that the National Institute for Health and Care Excellence (NICE), which provides evidence-based...
-
Sep 9, 2024Un sondaggio dimostra che depressione e stanchezza sono comuni tra le persone che vivono con il dolore cronico
MILANO, Italia, 9 Settembre 2024 – Il mese di settembre è dedicato alla sensibilizzazione sul dolore cronico, una condizione che colpisce più di 10 milioni di persone in Italia1. Boston...